Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Trial With "Off-The-Shelf" Third-Party BPX-501 Donor Lymphocyte Immunotherapy to Treat Persistence or Relapse of Hematologic Malignancies After Allogeneic Stem Cell Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03807063
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:36.900505+00:00
Published At
2020-08-14T00:00:00+00:00
Record Updated At
2020-08-14
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Bilineal Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-08-14"
protocolSection.identificationModule.nctId
"NCT03807063"
protocolSection.identificationModule.officialTitle
"Phase I Trial With \"Off-The-Shelf\" Third-Party BPX-501 Donor Lymphocyte Immunotherapy to Treat Persistence or Relapse of Hematologic Malignancies After Allogeneic Stem Cell Transplantation"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Bilineal Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Biphenotypic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.